Treatments compared for pediatric-onset multiple sclerosis
Scientists shed light on COVID-19 booster dose effectiveness among the elderly in Japan
6 October 2022Vaginal immune system may hint at prime vaccine timing
6 October 2022Treatments compared for pediatric-onset multiple sclerosis
More patients with pediatric-onset multiple sclerosis (POMS) are free of new or newly enlarging (N or NE) T2 hyperintense lesions with dimethyl fumarate (DMF) versus interferon β-1a (IFNβ-1a) treatment, and the annualized relapse rate is lower with DMF, according to a study published online Sept. 28 in JAMA Network Open.
